Emmanuel Chang, MD
Retina Specialist · Bellaire, TXNPI 1083877740
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Genentech USA, Inc. at 55.8% of the total. Among retina specialist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 389 payments — averaging $652.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$142K
- Bausch & Lomb Americas Inc.$44K
- Regeneron Healthcare Solutions, Inc.$34K
- Novartis$20K
- Carl Zeiss Meditec USA, Inc.$4K
- Regeneron$4K
- plus $6K from 17 others
Across 235 payments — averaging $14,813 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$3.2M
- Novartis$194K
- Roche TCRC, Inc.$54K
- Astellas Pharma Global Development$8K
- AbbVie$150
What the payments were for
- Consulting fees$89,86035%
- Speaking & faculty fees$120,81948%
- Travel & lodging$24,61510%
- Food & beverage$16,1866%
- Entertainment$1050%
- Ownership interest$2,1851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 164 | $141,620 |
| Bausch & Lomb Americas Inc. | 46 | $43,859 |
| Regeneron Healthcare Solutions, Inc. | 65 | $34,024 |
| Novartis | 18 | $20,028 |
| Carl Zeiss Meditec USA, Inc. | 3 | $4,449 |
| Regeneron | 5 | $3,858 |
| US Retina LLC | 6 | $2,185 |
| AbbVie(2 entities) | 19 | $815 |
| Apellis Pharmaceuticals, Inc. | 14 | $569 |
| Astellas Pharma US Inc | 13 | $415 |
| Genentech, Inc. | 6 | $401 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $351 |
| Harrow Eye, LLC | 4 | $244 |
| Biogen | 6 | $200 |
| Eyepoint US, Inc. | 2 | $183 |
| Optos, Inc. | 1 | $105 |
| Sun Pharmaceutical Industries Inc. | 5 | $102 |
| Alcon | 1 | $100 |
| Oculus Surgical Inc. | 1 | $87 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Alimera Sciences, Inc. | 2 | $38 |
| Dutch Ophthalmic, USA | 1 | $38 |
| Springworks Therapeutics, Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$91,464
- STELLARIS$32,961
- EYLEA HD$31,698
- Lucentis$26,229
- BEOVU$19,573
- STELLARIS ELITE$10,219
- OPHTHALMIC INSTRUMENTS$8,865
- EYLEA$7,354
- Non-Covered Product$6,111
- CIRRUS HD-OCT$4,449
- ATLAS 500$3,200
- CIRRUS 6000 with AngioPlex$3,200
- CLARUS$3,200
- SUSVIMO$839
- OZURDEX$378
- IHEEZO$189
- VITESSE$163
- STELLARIS PC$163
- Izervay$140
- YUTIQ$125
How this compares
$253,769 in reported general payments places this provider in the 95th percentile of 108 retina specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SimbrinzaBrinzolamide/Brimonidine Tart | 41 | $10,486 |
| IlevroNepafenac | 19 | $9,427 |
| Prednisolone Acetate | 151 | $7,216 |
| Brinzolamide | 27 | $4,801 |
| Latanoprost | 379 | $3,657 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 203 | $3,549 |
| Bromfenac Sodium | 22 | $2,878 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $2,292 |
| Ketorolac Tromethamine | 71 | $1,407 |
| ValacyclovirValacyclovir Hcl | 15 | $862 |
| Brimonidine Tartrate | 80 | $669 |
| Ofloxacin | 45 | $428 |
| Dorzolamide Hcl | 35 | $356 |
| Gentamicin Sulfate | 28 | $187 |
| ErythromycinErythromycin Base | 11 | $146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AlconSimbrinza | $100 | $10,48641 claims |
| NovartisIlevro | $20,028 | $9,42719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 108 retina specialist providers in Texas.
Other retina specialist in Bellaire
- Ting Fang SuarezBellaire$156K
- Angela KimBellaire$7K
- Paul StewartBellaire$4K
- Courtney CrawfordBurleson$342K
- Jeremiah BrownSchertz$339K
- Victor GonzalezMcAllen$335K
- Judy KimDallas$256K
- Hemang PandyaPlano$153K
- Margaret RunnerSouthlake$71K
- Moises ChicaSan Antonio$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.